COVID-19 mRNA Vaccines and Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
The Coronavirus Disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, BNT162b2 and mRNA-1273, manufactured by Pfizer-BioNTech and Moderna, respectively, received the United States Food and Drug Administration (FDA) emergency use authorization in December 2020 and have since been widely administered. Recognizing the increased mortality risk from COVID-19 in cancer patients1, the major cancer scientific societies such as the American Society of Clinical Oncology (ASCO)2, European Society for Medical Oncology (ESMO)3, and National Comprehensive Cancer Network (NCCN)4 generally recommend COVID-19 vaccination in cancer patients if there are no contraindications.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Yu-Wei Chen, Matthew D. Tucker, Kathryn E. Beckermann, Wade T. Iams, Brian I. Rini, Douglas B. Johnson Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Coronavirus | COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Pfizer | USA Health | Vaccines